Compare Stocks: JAGX, LIAN, SCNX, and LEXX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JAGX Jaguar Animal Health	$4.64 -3.1%	$9.37	$2.35 ▼ $1,260.00	$1.65M	-0.11	6.44 million shs	480,275 shs
LEXX Lexaria Bioscience	$3.27 -1.5%	$6.73	$2.77 ▼ $21.60	$6.99M	0.61	80,564 shs	66,136 shs
LIAN LianBio	$0.05 -15.6%	$0.05	$0.27 ▼ $4.99	$5.51M	0.23	1.04 million shs	300 shs
SCNX Scienture	$3.91 +4.0%	$8.43	$3.23 ▼ $65.00	$6.18M	3.34	407,219 shs	37,634 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JAGX Jaguar Animal Health	0.00%	+30.87%	+1.70%	-85.81%	-99.56%
LEXX Lexaria Bioscience	0.00%	+15.28%	-16.37%	-62.79%	-74.16%
LIAN LianBio	0.00%	-12.45%	-1.68%	-53.89%	-29.31%
SCNX Scienture	0.00%	-5.29%	-56.77%	-57.75%	-78.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JAGX Jaguar Animal Health	$4.64 -3.1%	$9.37	$2.35 ▼ $1,260.00	$1.65M	-0.11	6.44 million shs	480,275 shs
LEXX Lexaria Bioscience	$3.27 -1.5%	$6.73	$2.77 ▼ $21.60	$6.99M	0.61	80,564 shs	66,136 shs
LIAN LianBio	$0.05 -15.6%	$0.05	$0.27 ▼ $4.99	$5.51M	0.23	1.04 million shs	300 shs
SCNX Scienture	$3.91 +4.0%	$8.43	$3.23 ▼ $65.00	$6.18M	3.34	407,219 shs	37,634 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JAGX Jaguar Animal Health	0.00%	+30.87%	+1.70%	-85.81%	-99.56%
LEXX Lexaria Bioscience	0.00%	+15.28%	-16.37%	-62.79%	-74.16%
LIAN LianBio	0.00%	-12.45%	-1.68%	-53.89%	-29.31%
SCNX Scienture	0.00%	-5.29%	-56.77%	-57.75%	-78.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JAGX Jaguar Animal Health	1.00	Sell	N/A	N/A
LEXX Lexaria Bioscience	2.00	Hold	$22.50	588.07% Upside
LIAN LianBio	0.00	N/A	N/A	N/A
SCNX Scienture	2.00	Hold	$37.50	859.08% Upside

Current Analyst Ratings Breakdown

Latest JAGX, LIAN, SCNX, and LEXX Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/2/2026	LEXX Lexaria Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
10/2/2026	SCNX Scienture	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/21/2026	SCNX Scienture	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/16/2026	LEXX Lexaria Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	LEXX Lexaria Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	JAGX Jaguar Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	LEXX Lexaria Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JAGX Jaguar Animal Health	$11.51M	0.14	N/A	N/A	($1,590.93) per share	0.00
LEXX Lexaria Bioscience	$710K	9.72	N/A	N/A	$2.00 per share	1.64
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
SCNX Scienture	$430K	14.91	N/A	N/A	$43.15 per share	0.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JAGX Jaguar Animal Health	-$53.43M	-$3,731.33	N/A	N/A	N/A	-187.88%	N/A	-131.45%	11/12/2026 (Estimated)
LEXX Lexaria Bioscience	-$11.90M	-$5.10	N/A	N/A	N/A	N/A	-174.93%	-143.89%	10/28/2026 (Estimated)
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
SCNX Scienture	-$41.51M	-$2.10	N/A	N/A	N/A	N/A	-53.51%	-42.47%	11/11/2026 (Estimated)

Latest JAGX, LIAN, SCNX, and LEXX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/28/2026	Q4 2026	LEXX Lexaria Bioscience	-$0.90	N/A	N/A	N/A	$0.05 million	N/A
8/19/2026	Q2 2026	JAGX Jaguar Animal Health	-$782.25	-$15.70	+$766.55	-$235.50	$4.24 million	$1.23 million
8/13/2026	Q2 2026	SCNX Scienture	-$2.25	-$0.07	+$2.18	-$1.75	$1.96 million	$0.34 million
7/13/2026	Q3 2026	LEXX Lexaria Bioscience	-$0.06	-$0.08	-$0.02	-$1.20	$0.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JAGX Jaguar Animal Health	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JAGX Jaguar Animal Health	0.35	0.69	0.40
LEXX Lexaria Bioscience	N/A	10.61	10.61
LIAN LianBio	N/A	10.06	10.06
SCNX Scienture	0.15	3.04	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JAGX Jaguar Animal Health	12.04%
LEXX Lexaria Bioscience	13.06%
LIAN LianBio	74.85%
SCNX Scienture	5.68%

Insider Ownership

Company	Insider Ownership
JAGX Jaguar Animal Health	0.12%
LEXX Lexaria Bioscience	8.39%
LIAN LianBio	7.59%
SCNX Scienture	19.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JAGX Jaguar Animal Health	47	340,000	345,000	No Data
LEXX Lexaria Bioscience	7	2.11 million	1.93 million	Not Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
SCNX Scienture	9	1.64 million	1.32 million	N/A

JAGX, LIAN, SCNX, and LEXX Headlines

Recent News About These Companies

Contrasting Scienture (NASDAQ:SCNX) and Silo Pharma (NASDAQ:SILO)

October 7, 2026 | americanbankingnews.com

SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

October 5, 2026 | marketscreener.comM

What is Maxim Group's Estimate for Scienture Q3 Earnings?

October 5, 2026 | americanbankingnews.com

Exclusive: Scienture expands institutional reach for hypertension drug with new hospital adoptions

October 2, 2026 | msn.com

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

October 2, 2026 | globenewswire.com

Scienture announces 1-for-25 reverse stock split

September 30, 2026 | msn.com

Scienture Holdings, Inc. Announces Reverse Stock Split

September 30, 2026 | globenewswire.com

Scienture Expands REZENOPY Reach To Addiction Centers Under Distribution Deal

September 22, 2026 | rttnews.com

Scienture signs deal to sell Rezenopy at 2,000 addiction clinics

September 22, 2026 | streetinsider.com

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

September 22, 2026 | globenewswire.com

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026

September 9, 2026 | globenewswire.com

Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses

August 14, 2026 | quiverquant.comQ

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

August 14, 2026 | globenewswire.com

Scienture Holdings Stock Price History

August 12, 2026 | investing.com

Scienture launches Rezenopy as second FDA-approved commercial product

August 12, 2026 | msn.com

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

August 12, 2026 | globenewswire.com

Scienture Holdings纳洛酮鼻喷雾剂7月将向美批发商发货

July 28, 2026 | finance.sina.com.cnF

Scienture Holdings stock jumps over 20% pre-market: Here's why

July 10, 2026 | msn.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | finance.yahoo.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

JAGX, LIAN, SCNX, and LEXX Company Descriptions

Jaguar Animal Health NASDAQ:JAGX

$4.64 -0.15 (-3.13%)

Closing price 04:00 PM Eastern

Extended Trading

$4.61 -0.03 (-0.73%)

As of 07:59 PM Eastern

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Lexaria Bioscience NASDAQ:LEXX

$3.27 -0.05 (-1.51%)

Closing price 03:59 PM Eastern

Extended Trading

$3.26 -0.02 (-0.46%)

As of 05:18 PM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

LianBio NASDAQ:LIAN

$0.05 -0.01 (-15.56%)

As of 10/9/2026

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Scienture NASDAQ:SCNX

$3.91 +0.15 (+3.99%)

Closing price 04:00 PM Eastern

Extended Trading

$3.96 +0.05 (+1.28%)

As of 07:46 PM Eastern

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JAGX, LIAN, SCNX, and LEXX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JAGX, LIAN, SCNX, and LEXX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JAGX, LIAN, SCNX, and LEXX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

JAGX, LIAN, SCNX, and LEXX Company Descriptions

Jaguar Animal Health NASDAQ:JAGX

Lexaria Bioscience NASDAQ:LEXX

LianBio NASDAQ:LIAN

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JAGX, LIAN, SCNX, and LEXX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JAGX, LIAN, SCNX, and LEXX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JAGX, LIAN, SCNX, and LEXX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

JAGX, LIAN, SCNX, and LEXX Company Descriptions

Jaguar Animal Health NASDAQ:JAGX

Lexaria Bioscience NASDAQ:LEXX

LianBio NASDAQ:LIAN

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools